Natus Medical Inc (BABY) Shares Sold by Phocas Financial Corp.
Phocas Financial Corp. decreased its position in Natus Medical Inc (NASDAQ:BABY) by 4.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 137,103 shares of the medical equipment provider’s stock after selling 5,778 shares during the quarter. Phocas Financial Corp.’s holdings in Natus Medical were worth $5,237,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in BABY. SG Americas Securities LLC acquired a new position in shares of Natus Medical in the third quarter worth $138,000. Greenwood Capital Associates LLC acquired a new position in shares of Natus Medical in the fourth quarter worth $219,000. First Capital Advisors Group LLC. acquired a new position in shares of Natus Medical in the fourth quarter worth $222,000. Bessemer Group Inc. acquired a new position in shares of Natus Medical in the fourth quarter worth $255,000. Finally, Stone Ridge Asset Management LLC acquired a new position in shares of Natus Medical in the fourth quarter worth $303,000. 95.76% of the stock is currently owned by institutional investors.
Natus Medical stock opened at $35.55 on Thursday. The company has a market cap of $1,120.82, a price-to-earnings ratio of -57.34 and a beta of 0.55. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.32 and a quick ratio of 2.54. Natus Medical Inc has a 12 month low of $28.00 and a 12 month high of $43.60.
Natus Medical declared that its Board of Directors has approved a share repurchase program on Thursday, February 22nd that permits the company to buyback $30.00 million in shares. This buyback authorization permits the medical equipment provider to buy shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.
Several equities analysts have commented on BABY shares. Roth Capital set a $39.00 price target on shares of Natus Medical and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Benchmark restated a “buy” rating and issued a $49.00 price target (down previously from $55.00) on shares of Natus Medical in a research note on Tuesday, January 16th. BidaskClub upgraded shares of Natus Medical from a “sell” rating to a “hold” rating in a research note on Saturday, March 17th. Zacks Investment Research downgraded shares of Natus Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, December 26th. Finally, William Blair downgraded shares of Natus Medical from an “outperform” rating to a “market perform” rating in a research note on Monday, January 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. Natus Medical has a consensus rating of “Hold” and a consensus target price of $44.33.
In related news, Director Ken Ludlum sold 4,000 shares of the business’s stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $31.68, for a total transaction of $126,720.00. Following the completion of the transaction, the director now owns 93,825 shares in the company, valued at $2,972,376. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 5.50% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/natus-medical-inc-baby-shares-sold-by-phocas-financial-corp/1957608.html.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc (NASDAQ:BABY).
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.